Mather Group LLC. Purchases 3,623 Shares of Abbott Laboratories $ABT

Key Points

• Mather Group LLC increased its holdings in Abbott Laboratories by 16.5%, acquiring an additional 3,623 shares in the second quarter, bringing its total to 25,596 shares valued at approximately $3.48 million.
• Several institutional investors, including Evanson Asset Management LLC and Northside Capital Management LLC, also raised their stakes in Abbott Laboratories, reflecting growing confidence in the company.
• Abbott Laboratories recently declared a $0.59 quarterly dividend to be paid on November 17th, indicating a strong commitment to returning value to shareholders.

Mather Group LLC. grew its position in Abbott Laboratories (NYSE:ABT - Free Report) by 16.5% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 25,596 shares of the healthcare product maker's stock after purchasing an additional 3,623 shares during the period. Mather Group LLC.'s holdings in Abbott Laboratories were worth $3,481,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of ABT. Foster Victor Wealth Advisors LLC lifted its position in shares of Abbott Laboratories by 3.5% in the second quarter. Foster Victor Wealth Advisors LLC now owns 3,681 shares of the healthcare product maker's stock worth $490,000 after purchasing an additional 124 shares in the last quarter. Evanson Asset Management LLC increased its stake in Abbott Laboratories by 38.6% in the 2nd quarter. Evanson Asset Management LLC now owns 5,564 shares of the healthcare product maker's stock valued at $757,000 after buying an additional 1,550 shares during the last quarter. Public Employees Retirement System of Ohio boosted its stake in shares of Abbott Laboratories by 1.0% during the 2nd quarter. Public Employees Retirement System of Ohio now owns 731,821 shares of the healthcare product maker's stock worth $99,535,000 after buying an additional 6,930 shares during the last quarter. Lynch & Associates IN grew its holdings in shares of Abbott Laboratories by 5.7% in the 2nd quarter. Lynch & Associates IN now owns 58,833 shares of the healthcare product maker's stock valued at $8,002,000 after acquiring an additional 3,163 shares in the last quarter. Finally, Northside Capital Management LLC increased its position in shares of Abbott Laboratories by 97.9% in the second quarter. Northside Capital Management LLC now owns 7,720 shares of the healthcare product maker's stock valued at $1,050,000 after acquiring an additional 3,820 shares during the last quarter. Institutional investors and hedge funds own 75.18% of the company's stock.

Insider Buying and Selling

In related news, CFO Philip P. Boudreau sold 5,550 shares of the firm's stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $134.55, for a total transaction of $746,752.50. Following the transaction, the chief financial officer directly owned 51,003 shares of the company's stock, valued at approximately $6,862,453.65. This trade represents a 9.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.46% of the company's stock.

Analyst Upgrades and Downgrades

ABT has been the subject of several recent research reports. Leerink Partners initiated coverage on Abbott Laboratories in a research report on Monday, June 16th. They set a "market perform" rating and a $143.00 price target for the company. Royal Bank Of Canada increased their price objective on Abbott Laboratories from $145.00 to $147.00 and gave the company an "outperform" rating in a report on Tuesday, July 15th. BTIG Research lowered their target price on shares of Abbott Laboratories from $148.00 to $145.00 and set a "buy" rating on the stock in a report on Friday, July 18th. Jefferies Financial Group raised shares of Abbott Laboratories from a "hold" rating to a "buy" rating and upped their price target for the stock from $143.00 to $145.00 in a research report on Friday, July 18th. Finally, Morgan Stanley lifted their price objective on shares of Abbott Laboratories from $127.00 to $137.00 and gave the company an "equal weight" rating in a research report on Tuesday, July 15th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and four have assigned a Hold rating to the company's stock. According to data from MarketBeat, Abbott Laboratories has a consensus rating of "Moderate Buy" and an average target price of $145.22.

Abbott Laboratories Stock Down 1.5%

Abbott Laboratories stock opened at $133.80 on Thursday. Abbott Laboratories has a twelve month low of $110.86 and a twelve month high of $141.23. The stock has a market cap of $232.87 billion, a P/E ratio of 16.77, a P/E/G ratio of 2.58 and a beta of 0.69. The company's 50-day moving average price is $130.69 and its two-hundred day moving average price is $131.17. The company has a quick ratio of 1.30, a current ratio of 1.82 and a debt-to-equity ratio of 0.25.

Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 EPS for the quarter, meeting the consensus estimate of $1.26. The company had revenue of $11.14 billion for the quarter, compared to the consensus estimate of $11.01 billion. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The firm's revenue for the quarter was up 7.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.14 earnings per share. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. As a group, analysts expect that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 17th. Investors of record on Wednesday, October 15th will be paid a $0.59 dividend. The ex-dividend date is Wednesday, October 15th. This represents a $2.36 annualized dividend and a dividend yield of 1.8%. Abbott Laboratories's dividend payout ratio is 29.57%.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.